Sanfilippo syndrome: 2026 so far

Cell-based screening moved from broad ideas to specific shortlists to test next.

In September, a patient-derived neuron study (nerve cells grown from a patient's cells) in MPS IIIA screened 63 FDA-approved drugs. It reported that at least nine drugs reduced disease-like changes within about two weeks, and this was seen across more than one lab readout (measurement). The same work highlighted a specific four-drug combination that was reported to reduce network hyperactivity (overactive signaling between neurons) and restore excitatory/inhibitory balance (the mix of 'go' and 'stop' signals). The effects were reported to last after treatment stopped in the dish. These results are limited to cells in a dish, with no animal or human testing reported. Some screened drugs caused notable cell death in the dish and were dropped. This leaves a smaller, lab-defined set of repurposed-drug candidates and combinations for follow-up testing, but it is not evidence of benefit in people yet.

Research covered in: September 2026

Lab screening suggested early drug leads may depend on the individual patient.

In July, a drug repurposing screen in fibroblasts (skin cells) from two people with MPS IIIB found several approved drugs that lowered a lysosome-accumulation dye readout (a stain that reflects build-up in cell recycling compartments) in one patient's cells but not in the other's. The study emphasized that this readout was indirect, meaning it was a dye signal rather than a direct measure of heparan sulfate storage or enzyme activity. It also did not establish how the drugs worked. At the active concentrations, the drugs did not show meaningful toxicity in these cell tests, but this is still lab-only evidence. In practical terms, these results suggest that early drug leads may not apply to everyone even within the same subtype, which can shape what researchers choose to test next.

Research covered in: July 2026

Case reports added detail on complications beyond the brain, but only in a few individuals.

In May, a single autopsy report described advanced MPS IIIA without genetic confirmation in that individual, with storage-related changes in the brain and organs including the heart, liver/spleen, kidneys, and gastrointestinal tract. This supports multisystem involvement in later-stage disease, but it is based on one case. In February, a separate single-person report in MPS IIIA described an episode of acute metabolic acidosis (a sudden, dangerous drop in blood pH) that resolved with correction of acidosis and supportive care. The report could not establish how common or predictable this is. Together, these are individual observations rather than generalizable rates or care standards, but they add limited evidence that complications can involve multiple body systems and that occasional acute events may occur in some individuals.

Research covered in: February 2026, May 2026

More genetic-first diagnoses were reported, along with clearer examples of where testing can miss important findings.

Across the months covered, multiple reports described using genetic testing to diagnose and subtype Sanfilippo. This included adult-diagnosed MPS IIIC and diagnoses in settings without enzyme testing. In some reports, novel variants were supported by enzyme activity and urine markers, and in other reports there was no biochemical confirmation. One clear limitation was shown in February: whole-exome sequencing (a test that reads many protein-coding genes) initially missed a NAGLU duplication in a family with MPS IIIB. Enzyme testing plus targeted genetic follow-up clarified the diagnosis. Other reports emphasized that similar symptoms can come from different MPS types, and that Sanfilippo-related genes (for example, HGSNAT) may also be found in people whose main problem is retinal disease (eye tissue disease) without clear Sanfilippo syndrome. In real life, this means getting to a confident subtype label may require combining different kinds of tests and, in some settings, accepting that confirmatory steps may be incomplete.

Research covered in: February 2026, March 2026, May 2026, June 2026, August 2026

Imaging studies put numbers on retina patterns and described brain changes in a small number of cases.

In March, a clinical series of 27 genetically confirmed patients reported common retinal imaging findings (eye scans). These included parafoveal outer retinal degeneration (damage near the center of vision) in 59% and foveal layer thickening (thicker layers at the center of vision) in 67%. The retinal nerve fiber layer around the optic nerve was often unremarkable. Imaging did not cleanly separate all subtypes. In August, two genetically diagnosed adolescents (MPS IIIA and MPS IIIC) were described with neuroimaging (brain imaging) changes consistent with progressive brain involvement, including brain volume loss, alongside high care needs. These reports describe what imaging can show rather than testing an intervention, and the August evidence is limited to two cases. This adds a more concrete set of imaging findings that may be tracked in research and clinical descriptions, even though links to day-to-day symptoms and progression remain uncertain in these reports.

Research covered in: March 2026, August 2026